Praxis Precision Medicines, Inc (PRAX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $310.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 7.61; Below-average business quality.
Praxis is a clinical-stage CNS biopharmaceutical company developing precision therapies for neurological disorders via its Cerebrum (small molecule) and Solidus (ASO) platforms. It has submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A-DEE) based... Read more
Sell if holding. Engine safety override at $310.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 7.61; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Praxis Precision Medicines, Inc
Latest news
- BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $843 Price Target — benzinga May 20, 2026 positive
- Truist Securities Maintains Buy on Praxis Precision Medicine, Raises Price Target to $715 — benzinga May 13, 2026 positive
- Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $166 — benzinga May 8, 2026 negative
- Praxis Precision Medicine Q1 EPS $(3.20) Beats $(3.50) Estimate — benzinga May 7, 2026 positive
- Why Is Praxis Precision Stock Soaring Tuesday? — benzinga Apr 14, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineulixacaltamide10-K Item 1: 'Our most advanced program, ulixacaltamide, is a differentiated and highly selective small molecule inhibitor of T-type calcium channels'
Material Events(8-K, last 90d)
- 2026-02-10Item 5.02LOW8-K/A amending Jan 8, 2026 filing: Board appointed Jeffrey Kindler to Audit and Nominating Committees and Stuart Arbuckle to Compensation and Science & Technology Committees, effective February 6, 2026. Routine committee assignments for newly elected Class II directors.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $310.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 7.61; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $297.59. Score 5.3/10, moderate confidence.
Take-profit target: $586.96 (+88.9% upside). Prior stop was $297.59. Stop-loss: $297.59.
Concentration risk — Pipeline: ulixacaltamide; Quality below floor (1.6 < 4.0).
Praxis Precision Medicines, Inc trades at a P/E of N/A (forward -32.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts cover PRAX with a consensus score of 4.2/5. Average price target: $652.
What does Praxis Precision Medicines, Inc do?Praxis is a clinical-stage CNS biopharmaceutical company developing precision therapies for neurological disorders via...
Praxis is a clinical-stage CNS biopharmaceutical company developing precision therapies for neurological disorders via its Cerebrum (small molecule) and Solidus (ASO) platforms. It has submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A-DEE) based on positive Phase 3 data, with no approved products and no revenue yet.